A detailed history of Tower Research Capital LLC (Trc) transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 307 shares of EWTX stock, worth $9,885. This represents 0.0% of its overall portfolio holdings.

Number of Shares
307
Previous 5,590 94.51%
Holding current value
$9,885
Previous $100,000 92.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$15.88 - $29.5 $83,894 - $155,848
-5,283 Reduced 94.51%
307 $8,000
Q2 2024

Aug 13, 2024

BUY
$15.08 - $21.23 $77,209 - $108,697
5,120 Added 1089.36%
5,590 $100,000
Q1 2024

May 15, 2024

SELL
$9.25 - $19.97 $164,344 - $354,806
-17,767 Reduced 97.42%
470 $8,000
Q4 2023

Feb 13, 2024

BUY
$5.51 - $12.1 $67,117 - $147,390
12,181 Added 201.14%
18,237 $199,000
Q3 2023

Nov 14, 2023

BUY
$5.73 - $7.69 $27,693 - $37,165
4,833 Added 395.18%
6,056 $34,000
Q2 2023

Aug 14, 2023

SELL
$5.71 - $10.29 $86,660 - $156,171
-15,177 Reduced 92.54%
1,223 $9,000
Q1 2023

May 09, 2023

BUY
$6.66 - $11.33 $65,241 - $110,988
9,796 Added 148.33%
16,400 $109,000
Q4 2022

Feb 10, 2023

BUY
$7.58 - $11.08 $21,443 - $31,345
2,829 Added 74.94%
6,604 $59,000
Q3 2022

Nov 10, 2022

BUY
$8.08 - $13.58 $20,644 - $34,696
2,555 Added 209.43%
3,775 $37,000
Q2 2022

Aug 15, 2022

SELL
$5.67 - $9.87 $5,227 - $9,100
-922 Reduced 43.04%
1,220 $10,000
Q1 2022

May 12, 2022

BUY
$9.1 - $18.97 $7,835 - $16,333
861 Added 67.21%
2,142 $21,000
Q4 2021

Feb 14, 2022

BUY
$14.41 - $22.41 $11,672 - $18,152
810 Added 171.97%
1,281 $20,000
Q3 2021

Nov 15, 2021

BUY
$14.11 - $24.1 $2,497 - $4,265
177 Added 60.2%
471 $8,000
Q2 2021

Aug 16, 2021

BUY
$21.33 - $30.25 $6,271 - $8,893
294 New
294 $6,000

Others Institutions Holding EWTX

About Edgewise Therapeutics, Inc.


  • Ticker EWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 63,171,700
  • Market Cap $2.03B
  • Description
  • Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...
More about EWTX
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.